Partial splenic embolism for cancer patients with pseudocirrhosis induced thrombocytopenia
Objective:Partial splenic embolism(PSE)has been safely and widely used for hypersplenism caused by various liver diseases.The purpose of this study was to review and summarize the effectiveness and safety of PSE in cancer patients with pseudocirrhosis induced thrombocytopenia(PIT).Methods:A total of 9 pa-tients diagnosed with PIT and undergoing PSE due to the need for continued systemic anti-tumor therapy from January 2023 to October 2024 were retrospectively analyzed.Clinical data,medical history,examination results,and adverse events of patients were recorded.The primary endpoint of the study included a platelet count increase＞100×109/L,and the secondary endpoint was the initiation of systemic anti-tumor therapy.Results:PSE was performed in 9 patients with tumor related PIT(5 males,4 females;aged 34-72 years,with an average of 57.8 years),and the technical success rate was 100％.Primary and secondary endpoints were achieved in all patients.The mean platelet count significantly increased from(36.67±13.96)× 109/L before PSE to a peak level of(132.22±31.00)× 109/L.The mean platelet counts at 1 week and 1 month after PSE were(74.44±23.26)× 109/L and(118.67±17.97)× 109/L respectively.All patients could receive systemic anti-tumor therapy once a-gain,with 7 patients(78％)within 1 month after surgery.No non-target embolization occurred,and one patient experienced a grade 3 adverse event with an increase in total bilirubin to 131 μmol/L due to his gallstones.All pa-tients experienced a mild to moderate postembolization syndrome,which can be relieved with supportive treat-ment.Conclusion:PSE is a safe and effective treatment for cancer patients with PIT.The platelet count is re-stored and patients are able to continue systematic anti-tumor treatment.
NETL
NSTL
万方数据
